Advertisement
Screener

Rocket Pharmaceuticals, Inc. (RCKT) Graph

RCKT Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $0.00; Research and development $29.50M; Operating expenses $46.92M; Income tax $8.62M.
  • 2026-03-31: Revenue $0.00; Research and development $31.45M; Operating expenses $48.51M; Income tax (m).
  • 2025-12-31: Revenue $0.00*; Research and development $29.35M*; Operating expenses $43.96M*; Income tax (m).
  • 2025-09-30: Revenue $0.00; Research and development $34.07M; Operating expenses $52.25M; Income tax (m).

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

RCKT revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Revenue$0.00Operating expenses$46.92MOperating income-$46.92MResearch & development$29.50MPre-tax income$131.84MIncome tax$8.62MNet income$123.21M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$0.00$29.50M$46.92M$8.62M$123.21M
2026-03-31$0.00$31.45M$48.51M(m)-$47.59M
2025-12-31$0.00*$29.35M*$43.96M*(m)-$42.54M*
2025-09-30$0.00$34.07M$52.25M(m)-$50.33M
2025-06-30$0.00$42.66M$71.15M$0.00-$68.92M
2025-03-31$0.00$35.94M$64.39M(m)-$61.33M
2024-09-30$0.00$42.31M$69.42M(m)-$66.72M
2024-06-30$0.00$46.34M$73.71M(m)-$69.65M
2024-03-31$0.00$45.23M$67.38M(m)-$62.05M
2023-09-30$0.00$46.84M$65.43M(m)-$61.90M
2023-06-30$0.00$51.38M$68.76M(m)-$65.70M
2023-03-31$0.00$46.37M$62.19M(m)-$58.34M
2022-09-30$0.00$43.38M$58.49M(m)-$57.76M
2022-06-30$0.00$41.36M$54.21M(m)-$54.40M
2022-03-31$0.00$30.79M$42.56M(m)-$42.98M
2021-09-30$0.00$39.62M$49.65M(m)-$50.12M
2021-06-30$0.00$24.53M$34.05M(m)-$34.52M
2021-03-31$0.00$28.31M$39.22M(m)-$40.18M
2020-12-31$0.00(m)$59.24M(m)-$60.92M
2020-09-30$0.00$21.66M$27.39M(m)-$29.08M
2020-06-30$0.00$16.73M$23.56M(m)-$25.04M
2020-03-31$0.00$16.96M$24.12M(m)-$24.66M
2019-12-31$0.00(m)$19.65M(m)-$19.86M
2019-09-30$0.00$14.83M$19.16M(m)-$19.28M
2019-06-30$0.00$13.99M$18.39M(m)-$18.68M
2019-03-31$0.00$15.14M$18.95M(m)-$19.45M
2018-12-31$0.00(m)$26.55M(m)-$27.32M
2018-09-30$0.00$13.06M$15.33M(m)-$16.09M
2018-06-30$0.00$10.77M$14.87M(m)-$15.77M
2018-03-31$0.00$5.74M$14.40M(m)-$15.34M
2017-12-31$0.00(m)$6.66M(m)-$6.66M
2017-09-30$0.00$4.89M$6.72M(m)-$6.72M
2017-06-30$0.00$2.82M$3.52M(m)-$3.52M
2017-03-31$0.00$2.29M$2.87M(m)-$2.68M
2016-09-30(m)$8.41M(m)(m)-$11.13M
2016-06-30(m)$6.46M(m)(m)-$8.68M
2016-03-31(m)$7.62M(m)(m)-$10.07M
2015-09-30(m)$3.61M(m)(m)-$55.96M
2015-06-30(m)$1.95M(m)(m)-$2.39M
2015-03-31(m)$1.07M(m)(m)-$1.46M
2014-09-30(m)$1.24M(m)(m)-$2.39M
2014-06-30(m)$1.86M(m)(m)-$2.85M
2014-03-31(m)$1.55M(m)(m)-$2.15M

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$0.00$60.95M$95.43M$8.62M$75.62M
2025-06-30$0.00$78.60M$135.54M$0.00-$130.25M
2024-06-30$0.00$91.57M$141.09M(m)-$131.70M
2023-06-30$0.00$97.75M$130.95M(m)-$124.04M
2022-06-30$0.00$72.15M$96.77M(m)-$97.38M
2021-06-30$0.00$52.84M$73.27M(m)-$74.70M
2020-06-30$0.00$33.69M$47.68M(m)-$49.70M
2019-06-30$0.00$29.13M$37.34M(m)-$38.13M
2018-06-30$0.00$16.52M$29.28M(m)-$31.11M
2017-06-30$0.00$5.10M$6.39M(m)-$6.20M
2016-06-30(m)$14.08M(m)(m)-$18.75M
2015-06-30(m)$3.02M(m)(m)-$3.85M
2014-06-30(m)$3.41M(m)(m)-$5.00M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesNet income
2025-09-30$0.00$112.67M$187.78M-$180.59M
2024-09-30$0.00$133.89M$210.51M-$198.42M
2023-09-30$0.00$144.60M$196.38M-$185.94M
2022-09-30$0.00$115.53M$155.26M-$155.14M
2021-09-30$0.00$92.46M$122.92M-$124.82M
2020-09-30$0.00$55.34M$75.06M-$78.78M
2019-09-30$0.00$43.95M$56.50M-$57.41M
2018-09-30$0.00$29.59M$44.61M-$47.20M
2017-09-30$0.00$10.00M$13.12M-$12.92M
2016-09-30(m)$22.49M(m)-$29.88M
2015-09-30(m)$6.63M(m)-$59.81M
2014-09-30(m)$4.66M(m)-$7.38M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$0.00$142.01M$231.75M$0.00-$223.12M
2024-12-31$0.00$171.24M$273.20M$0.00-$258.75M
2023-12-31$0.00$186.34M$259.66M$0.00-$245.59M
2022-12-31$0.00$165.57M$224.34M(m)-$221.86M
2021-12-31$0.00$125.48M$167.25M(m)-$169.07M
2020-12-31$0.00$105.44M$134.30M(m)-$139.70M
2019-12-31$0.00$57.91M$76.15M(m)-$77.27M
2018-12-31$0.00$53.27M$71.16M(m)-$74.52M
2017-12-31$0.00$14.92M$19.77M(m)-$19.58M
2016-12-31$0.00$5.99M$7.57M(m)-$7.57M
2015-12-31(m)$12.55M(m)(m)-$67.98M
2014-12-31(m)$5.59M(m)(m)-$9.53M

Similar stocks

Stock NameCountryMarket CapPE Ratio
STANDARD BIOTOOLS INC. (LAB)United States$0.297B3.80
Vanda Pharmaceuticals Inc. (VNDA)United States$0.302B-1.35
Fulcrum Therapeutics, Inc. (FULC)United States$0.289B-3.28
Contineum Therapeutics, Inc. (CTNM)United States$0.289B-4.40
Perspective Therapeutics, Inc. (CATX)United States$0.284B-3.34
Upstream Bio, Inc. (UPB)United States$0.284B-2.42
GT Biopharma, Inc. (GTBP)United States$0.309B-4.58
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63
Sagimet Biosciences Inc. (SGMT)United States$0.279B
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01